U.S. Markets open in 7 hrs 23 mins

Cotinga Pharmaceuticals Inc. (COTQF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.05100.0000 (0.00%)
At close: 3:38PM EDT

Cotinga Pharmaceuticals Inc.

The Canadian Venture Building
82 Richmond Street East
Toronto, ON M5C 1P1


Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Ms. Alison D. SilvaCEO, Pres & Director438.81kN/AN/A
Dr. Richard T. HoChief Scientific Officer257.85kN/A1963
Mr. Victor Hugo C.M.A., CPAChief Financial OfficerN/AN/A1970
Mr. Paul PapiVP of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

Corporate Governance

Cotinga Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.